Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.

Autor: Chow VA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Medical Oncology Division, Department of Medicine and., Gopal AK; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Medical Oncology Division, Department of Medicine and., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Medical Oncology Division, Department of Medicine and., Tseng YD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Department of Radiation Oncology, University of Washington, Seattle, WA., Turtle CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Medical Oncology Division, Department of Medicine and., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Medical Oncology Division, Department of Medicine and., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Medical Oncology Division, Department of Medicine and.
Jazyk: angličtina
Zdroj: Blood advances [Blood Adv] 2020 Oct 13; Vol. 4 (19), pp. 4869-4872.
DOI: 10.1182/bloodadvances.2020002292
Databáze: MEDLINE